Teva Pharmaceutical Industries Ltd. — Director's Dealing 2023

Mar 2, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA)
CIK: 0000818686
Period of Report: 2023-02-28

Reporting Person: Kalif Eliyahu Sharon (EVP, Chief Financial Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2023-02-28	Ordinary Shares	M	18430	—	Acquired	34435	Direct
2023-02-28	Ordinary Shares	M	44953	—	Acquired	79388	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2023-02-28	Restricted Share Units	$	M	18430	Disposed		Ordinary Shares (18430)	Direct
2023-02-28	Restricted Share Units	$	M	44953	Disposed		Ordinary Shares (44953)	Direct

Footnotes

F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F2: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources
and Compensation Committee, the cash value of one ordinary share.

F3: Restricted share units were granted on February 28, 2020 with 18,430 vested on each of February 28, 2021, February 28, 2022, February 28, 2023 and 18,430 vesting on February 28, 2024.

F4: Restricted share units were granted on February 7, 2023 pursuant to the satisfaction of performance criteria and vested on February 28, 2023.